Techulon, a Blacksburg, Virginia-based life sciences company offering low toxicity and novel biodegradable RNA and DNA delivery agents for cell-based therapeutics and research, has entered into a distribution deal with Allschwil, Switzerland-based BioConcept for its polymeric nanoparticle-delivery transfection reagent called Glycofect.
Glycofect has been exclusively designed for primary cells of therapeutic interest. Corporate, university and government laboratories in more than 20 nations are using the reagent for innovative research to develop novel cell-based therapeutics and to extend the knowledge on cell biology.
BioConcept is a distributor of disposables, reagents, lab instrumentation and devices for applications in the areas of immunology, molecular biology and cell biology. The President and Chief Executive Officer at BioConcept, Martin Howald stated that the company, a major producer of cell culture media (AMIMED), is happy to collaborate with Techulon for Glycofect distribution. The novel characteristics of Glycofect are a perfect match for the portfolio of BioConcept and the company’s MAM-PF, a chemically defined CHO production medium devoid of animal, serum and protein components, in combination with Glycofect will offer more benefits to its customers, he added.
According to Techulon’s President, Frank Akers, the company is happy about the distribution deal with BioConcept. European and Swiss institutions are pioneers in cell-based therapeutics research and the company anticipates strong demand for its Glycofect reagents, as research focuses on primary cells, he said. The company expects that with strong customer base and an extensive product portfolio, BioConcept will extend Techulon’s market penetration across Europe, he added.
Source: http://www.techulon.com